Indication
Epstein-Barr Virus Related Leiomyosarcoma
1 clinical trial
3 products
Product
NanatinostatProduct
ValganciclovirProduct
PembrolizumabClinical trial
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-01